Medical Tidbits, Surprisingly long learning curve for surgeons operating on oesophageal cancer

breaking medical news, new alzheimers research, clinical trials for bladder cancer

According to a major Swedish cohort study from researchers at Karolinska Institutet in Sweden and Imperial College London, a surgeon who operates on oesophageal cancer must have performed 60 operations to prevent any lack of experience adversely affecting the long-term survival of the patients. The finding, which is published in the Journal of Clinical Oncology , has potential significance for clinical practice. read more

Studies Show Ixekizumab Improved Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis: Results Published in JAMA Dermatology

PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that JAMA Dermatology has published detailed results from three pivotal Phase 3 trials that evaluated the effect of ixekizumab on work productivity in patients with moderate-to-severe plaque psoriasis. Specific results from the UNCOVER-1 study were also presented Monday during the American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C.

In an analysis of the UNCOVER-1, UNCOVER-2 and UNCOVER-3 studies, the effect of ixekizumab on work productivity was evaluated by the change from baseline as measured by Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) scores at 12 weeks. The validated, self-reported WPAI questionnaire is used to measure impairment of work activities due to general health or a specific condition.1

In all three studies, patients treated with ixekizumab reported improved work productivity compared to patients treated with placebo. In UNCOVER-1, improvements in work productivity were also sustained up to 60 weeks in those who demonstrated initial clinical response to ixekizumab at 12 weeks. read more

Fluconazole Injection, USP, (in 0.9 Percent Sodium Chloride) 200mg per 100ml: Recall – Elevated Impurity

Sagent has initiated a voluntary recall of one lot of Fluconazole Injection, USP, 200mg per 100mL to the user level due to the discovery of an out of specification impurity result detected during routine quality testing of stability samples at the 18-month interval.  This impurity has been identified as Metronidazole.  An elevated impurity has the potential to decrease effectiveness of the product in patients.  Patients on the product and on concomitant medication of Metronidazole may receive an increased dose of Metronidazole.  read more

Medtronic Enrolls First Patients in Clinical Study to Evaluate the CoreValve(TM) Evolut(TM) R System in ‘Real-World’ Setting

Medtronic plc (NYSE: MDT) today announced the first patients enrolled in the Evolut R FORWARD Clinical Study, a global, multi-center, single-arm, prospective study of up to 1,000 patients, to evaluate performance outcomes using the CoreValve(TM) Evolut(TM) R System in everyday clinical practice. A next-generation, recapturable and repositionable transcatheter aortic valve implantation (TAVI) system, Evolut R has shown the highest reported survival rate (93.3 percent) for high and extreme risk aortic stenosis patients at one-year follow-up according to data from the Evolut R CE Study that was recently presented at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Aortic stenosis is a condition where the aortic valve narrows thereby limiting blood flow from the aorta to the rest of the body. read more

Clinical review explores role of RT in BRCA1, BRCA2 mutation breast cancer treatment

In light of conflicting and inconclusive clinical data on the benefit of radiation therapy in cancer patients with the BRCA1 and BRCA2 mutation, a clinical review examined the current status of data regarding BRCA1 and BRCA2 deficiency and radiation therapy sensitivity and a potential strategy to intensify the effects of radiation therapy (RT) by poly(ADP-ribose) polymerase inhibitors (PARPi), the pharmacologic drugs under investigation as monotherapy for the treatment of breast cancer in patients with BRCA1 and BRCA2 mutations.  read more

Alzheimer’s more versatile than previously known

Accumulation of the substance amyloid beta in the brain impairs the memory and cognitive ability in people with Alzheimer’s. New findings from Lund University in Sweden show that the cause of amyloid beta pathology might be more versatile than previously known. Researchers believe that these new findings may be of significance to the development of new medications. read more

Affymetrix Receives Grant for Non-Invasive Genomic Profiling of Bladder Cancer

SANTA CLARA, Calif.–(BUSINESS WIRE)–Affymetrix Inc. (NASDAQ:AFFX) today announced that it has received a grant from Innovate UK (IUK) to demonstrate the health and economic value of utilizing the company’s OncoScan® FFPE Assay Kit for non-invasive genomic profiling of bladder cancer from urine samples. Bladder cancer is the seventh most common cancer in the western world, with over 10,000 new cases diagnosed in the UK each year. Patients with non-muscle invasive bladder cancer (NMIBC) generally have greater than 90 percent survival rates over five years, but high recurrence rate and significant risk of progression to muscle invasive bladder cancer (MIBC) require continual monitoring. Current bladder cancer monitoring methods rely on repeat cystoscopy and biopsy. These procedures are highly invasive, unpleasant for the patient, and expensive for the healthcare system.  read more

Brainlab AG Chooses Box for Content Management and Collaboration

MUNICH, Germany–(BUSINESS WIRE)–Box [NYSE: BOX] today announced that Brainlab AG, a German company which develops medical technology for image-guided surgery, radiation oncology and medical image exchange, is making Box’s content management platform available to its workforce around the globe. Brainlab chose Box as its content platform to give its entire team access to information on any device at anytime

New Analyses: Adding SPIRIVA® Respimat® Effective for Uncontrolled Asthma – Regardless of Allergy Subtype

INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced the presentation of new post-hoc analyses that show the addition of SPIRIVA® (tiotropium) Respimat® to other asthma maintenance therapies helps improve lung function and asthma symptom control, while reducing asthma exacerbations (also known as flare-ups), independent of a patient’s subtype of allergic asthma.1,2,3 These data were presented at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Los Angeles. read more

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!







Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.